# Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China

> **NCT05105971** · PHASE1 · COMPLETED · sponsor: **Bio-Thera Solutions** · enrollment: 30 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BAT6026

## Key facts

- **NCT ID:** NCT05105971
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-23
- **Primary completion:** 2023-11-14
- **Final completion:** 2023-11-14
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05105971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05105971, "Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05105971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*